Targinta develops tumor-targeting antibodies and ADCs for aggressive cancer. The pipeline is based on the in-house discovery of a novel patent-protected cancer target, integrin α10β1, selectively expressed in aggressive cancers, such as triple-negative breast cancer and glioblastoma, both with very high unmet medical need.

Targinta has built a strong position in the ADC-field, an area that has grown very fast in recent years with several market approvals. With first-in-class drug candidates in a hot area based on a novel patent-protected cancer target, Targinta´s ambition is to enter into pivotal partnerships to accelerate the development of our new cancer treatment through clinical development and to patients.

Tumor-targeting antibodies are becoming increasingly important within oncology. They act with higher selectivity on the tumor compared to chemotherapies and thus have the potential to be more effective as well as safer. Tumor-targeting antibodies can be divided into two main groups. The first group consists of monoclonal antibodies which act either by blocking functions important for the survival of cancer cells, or, by pointing out the cancer cells to the surveilling immune system. Today, about 30 monoclonal cancer antibodies are marketed for different indications such as lymphoma and breast cancer. The total value of the market is expected to reach USD 70 billion by 2025.
The second group of tumor-targeting antibodies is the so-called antibody-drug conjugates, or ADCs, wherein the antibodies are used as cancer-homing carriers for extremely potent toxins. The toxins are selectively delivered to the cancer cells expressing the target, but not elsewhere in the body. ADCs are thus monoclonal antibodies armed with powerful toxins that can be delivered with precision to the cancer cells. ADCs often have stronger effects and may also be better tolerated than standard of care chemotherapies. The ADC technology has advanced tremendously in recent years,and led to several market approvals. The total value of the ADC market is expected to increase to USD 20 billion by 2028.